-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/gout_clinician.pdf
January 01, 2017 - Treatments for gout attacks include nonsteroidal anti-
inflammatory drugs (NSAIDs), colchicine, and … NSAIDs ���
ACTH = adrenocorticotropic hormone; N = number; NSAIDs = nonsteroidal anti-inflammatory drugs … the risk of gout attacks ���
N = number; NR = not reported; NSAIDs = nonsteroidal anti-inflammatory drugs … thromboembolic events, hepatic failure, TEN, SJS, and DRESS
NSAIDs = nonsteroidal anti-inflammatory drugs
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-218-osteoporosis-disposition-comments.pdf
April 23, 2019 - Table 5)
Comment: Table 4 defines the interventions to be
included in this systematic review as “Drugs … to determine whether these harms were
associated with long-term treatment with these
osteoporosis drugs … Class-Specific Harms of Drugs
Used for Osteoporosis Treatment has several important
errors. … to
determine whether these harms were associated with
long-term treatment with these osteoporosis drugs … Results Public Commenter
#1 (Rafael Pirtillo
Ferman -Altietus
College)
Drugs still working
Thank
-
effectivehealthcare.ahrq.gov/sites/default/files/09_infectiousdisease_potential_high_impact_june_2012.pdf
January 01, 2012 - Optimer Pharmaceuticals announced a 2-year
agreement with Cubist Pharmaceuticals, Inc. … Tibotec Pharmaceuticals, Vertex
Pharmaceuticals. … Cambridge (MA): Vertex
Pharmaceuticals, Inc.; 2012 Feb 23 [accessed
2012 May 21]. [5 p]. … Cambridge (MA): Vertex Pharmaceuticals
Incorporated; [accessed 2012 May 17]. [3 p]. … San Diego
(CA): Optimer Pharmaceuticals, Inc.; 2011
[accessed 2011 Jul 21]. [4 p].
-
effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1512.pdf
December 29, 2015 - health care sector, horizon
scanning pertains to identification of new (and new uses of existing) pharmaceuticals … Results
The table below lists four topics for which (1) preliminary phase III data for drugs were … Treatments such as nonsteroidal anti-inflammatory
drugs (NSAIDs) are used for first-line therapy to … Novartis Pharmaceuticals. 16 week efficacy
and 2 year long term safety and efficacy of
secukinumab … Novartis Pharmaceuticals. 16 week efficacy
and 5 year long term efficacy, safety and
tolerability
-
effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1312.pdf
December 01, 2013 - Coordinating Council for Comparative Effectiveness
Research, AHRQ is interested in innovations in drugs … health care sector, horizon
scanning pertains to identification of new (and new uses of existing) pharmaceuticals … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs,
devices, procedures … Information is compiled for expert comment on topics at a granular
level (i.e., similar drugs in the … Autism treatments and drugs.
[internet].
-
effectivehealthcare.ahrq.gov/sites/default/files/cer-228-nonopioid-pharm-chronic-pain-comments.pdf
April 16, 2020 - of 4 will addict, then there would be ~25 million Americans addicted,
and actively seeking illicit drugs … This was a 13-week randomized trial comparing
escitalopram with duloxetine and showed that both drugs … Each of the pharmaceuticals studied have
unique profiles that make them clinically
appropriate for … ASRA recognizes that all drugs – opioid and
nonopioid – carry risks. … This report examines the
evidence-base for nonopioid drugs used to treat chronic pain, varying by pain
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/misuse-prescription-protocol-amendment.pdf
November 26, 2024 - For example, emergency department visits related to
NMU of these drugs by adults increased from 5,212 … Misuse of Prescription Drugs Research Report. 2023. … https://nida.nih.gov/publications/research-reports/misuse-prescription-drugs/overview. … MMWR
https://nida.nih.gov/publications/research-reports/misuse-prescription-drugs/overview
https://
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/migraine-emergency_executive.pdf
November 01, 2012 - ergot
derivatives (e.g., dihydroergotamine [DHE]), intravenous
(IV) nonsteroidal anti-inflammatory drugs … Food and
Drug Administration documents related to the drugs of
interest were reviewed for additional … We recognize that many drugs have various effects. … For the mixed-treatment analysis,
we identified a group of drugs that were not easily
classified and … We refer to these drugs collectively as
“orphan agents.”
-
effectivehealthcare.ahrq.gov/sites/default/files/05_depression_potential_high_impact_june_2012.pdf
January 01, 2012 - In the health care sector, horizon
scanning pertains to identifying new (and new uses of existing) pharmaceuticals … several weeks, following a single infusion.
37,41,42
The drug was originally launched by King Pharmaceuticals … Drugs Future
2009;34(3):217-21.
39. Thomson Reuters Integrity [database online]. … In: Drugs@FDA [internet]. Silver
Spring (MD): U.S. … Available:
http://www.accessdata.fda.gov/scripts/cder/drugs
atfda/index.cfm?
-
effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1312.pdf
December 01, 2013 - Vertex Pharmaceuticals, Cystic Fibrosis Foundation. … Vertex Pharmaceuticals Incorporated, Cystic
Fibrosis Foundation. … Pricing for
orphan drugs: will the market bear what society
cannot? … Vertex Pharmaceuticals Incorporated. … Vertex Pharmaceuticals Incorporated.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/horizon-scan_research-protocol.pdf
December 01, 2011 - Coordinating Council for
Comparative Effectiveness Research, AHRQ is interested in innovations in drugs … health care sector, horizon scanning
pertains to identification of new (and new uses of existing) pharmaceuticals … If so, do not select, because these are “me-too” of existing drugs. … Covers future industry
trends, key industry developments,
research and development of drugs and
pharmaceuticals … Industries covered:
pharmaceuticals, biotechnology,
medical equipment & devices, and in
vitro diagnostics
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/atrial-fibrillation_disposition-comments.pdf
June 28, 2013 - And for KQ4, comparing anti-arrhythmic drugs (AADs) with electrical
cardioversion for restoration of … We
have added additional information about whether
the drugs were given IV, orally, or a combination … Mascette
ES (Results) The inclusion of amiodarone and sotalol as rate-control drugs (pp. … Mascette
Results A gender difference in efficacy of drugs (but not proarrhythmia) is
mentioned on … Comparative efficacy of rate control drugs is a
good example.
-
effectivehealthcare.ahrq.gov/products/juvenile-arthritis-dmards/research-protocol
-
effectivehealthcare.ahrq.gov/sites/default/files/s158.pdf
October 01, 2007 - Measures: Association between nonsteroidal antiinflammatory
drugs (NSAIDs) and mortality. … In addition, frail elderly
patients, who use the most drugs and have the highest adverse
event rates, … These
databases are, however, often the best source of information
on the association between drugs and … diseases, because they
allow timely assessment of infrequently used drugs and rare
outcomes in large … Selective prescribing led to
overestimation of the benefits of lipid-lowering drugs.
-
effectivehealthcare.ahrq.gov/sites/default/files/05_depression_potential_high_impact_2012-12-10.pdf
January 01, 2012 - In the health care sector, horizon
scanning pertains to identifying new (and new uses of existing) pharmaceuticals … Results
The table below lists the seven topics for which (1) preliminary phase III data on drugs or … to several weeks,
following a single infusion.
29,33,34
The drug was launched in 1966 by King Pharmaceuticals … Drugs Future
2009;34(3):217-21.
31. Thomson Reuters Integrity [database online]. … In: Drugs@FDA [internet]. Silver
Spring (MD): U.S.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-208-bipolar-adults-disposition-comments.pdf
August 07, 2018 - Introduction Peer Reviewer
#6
“Drugs for acute mania are generally used for shorter periods than … drugs used for treating depression or for maintenance.” – This is
often not the case. … The statement is not true of
other drugs.
Thank you for the clarification. … We
revised the sentence to read that
some drugs may increase these
risks. … Perhaps for clarity “Other drugs for
acute mania” could be relabeled “Drugs Not Approved by FDA For
-
effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1406.pdf
June 01, 2014 - health care sector, horizon
scanning pertains to identification of new (and new uses of existing) pharmaceuticals … For purposes of horizon scanning, AHRQ’s interests are broad and encompass drugs,
devices, procedures … Information is compiled for expert comment on topics at a granular
level (i.e., similar drugs in the … Results
The table below lists the two topics for which (1) preliminary phase III data on drugs, phase … A third topic that was in the December 2013 report, the oral tablet ivacaftor
(Kalydeco™, Vertex Pharmaceuticals
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/point-of-care_research.pdf
April 01, 2014 - We typically did not review
evidence summaries on specific interventions, such as specific drugs or … Dietary
Supplements in Adults Taking Cardiovascular
Drugs. … Interactions of
commonly used dietary supplements with
cardiovascular drugs: a systematic review. … Dietary Supplements in Adults Taking Cardiovascular Drugs. … Interactions of commonly used
dietary supplements with cardiovascular drugs: a systematic review.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_executive.pdf
April 01, 2012 - Available
therapies for PsA include corticosteroids,
oral disease-modifying antirheumatic
drugs or … Effective
Health Care
infliximab) are also classified as antitumor
necrosis factor (anti-TNF) drugs … Finally,
very little is known about the benefits or risks of these
drugs in different patient subgroups … Analytic framework for treatment for psoriatic arthritis
DMARDS = disease-modifying antirheumatic drugs … Discussion
No head-to-head controlled trials meeting inclusion criteria
existed for any drugs in this
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/disruptive-behavior-disorder_research-protocol.pdf
January 30, 2014 - CNS Drugs. 2006;20(7):549-65. PMID: 16800715
41. Newcorn JH, Ivanov I. … BTA Pharmaceuticals Inc., Bridgewater, NJ
Bupropion Mylan Pharmaceuticals Inc., Morgantown, WV
Selective … New York, NY
Citalopram Teva Pharmaceuticals, Sellersville, PA
Escitalopram Teva Pharmaceuticals, Sellersville … , PA
Paroxetine Teva Pharmaceuticals, Sellersville, PA
Fluvoxamine Mylan Pharmaceuticals Inc., Morgantown … ") OR
SU.EXACT.EXPLODE("Adrenergic Drugs")) OR
(SU.EXACT.EXPLODE("Anticonvulsive Drugs") OR
SU.EXACT.EXPLODE